echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Jiahe Biotech announces the latest research results of gerolizumab combined with fruquintinib in the treatment of patients with metastatic colorectal cancer at the 2021ASCO conference

    Jiahe Biotech announces the latest research results of gerolizumab combined with fruquintinib in the treatment of patients with metastatic colorectal cancer at the 2021ASCO conference

    • Last Update: 2021-06-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The 2021 American Society of Clinical Oncology Annual Meeting (ASCO2021) will be held in the form of a virtual meeting from June 4th to 8th.
    Jiahe Bio-Bio released the latest research results of the Phase Ib trial of gelolimumab (GB226, geptanolimab) combined with fruquintinib in the treatment of patients with metastatic colorectal cancer (mCRC) at the ASCO conference.

    According to the clinical trial data analysis of 15 patients with metastatic colorectal cancer (mCRC) selected as of December 15, 2020, the validity results are encouraging:

    All evaluable enrolled patients:

    The objective response rate (ORR) was 26.
    7% in the phase II clinical recommended dose (RP2D) group, the objective response rate (ORR) was 33.
    3%, the disease control rate (DCR) was 80%, and the median progression-free survival time (mPFS) was 7.
    33 Month (95%CI: 1.
    91-NE)

    In 12 patients with MSS-type metastatic colorectal cancer (mCRC):

    The objective response rate (ORR) was 25.
    0%, the disease control rate (DCR) was 75%, and the median progression-free survival (mPFS) was 5.
    45 months (95%CI: 1.
    84-9.
    66)

    Security is controllable:

    The most common treatment-related AEs (TRAE) were proteinuria (46.
    7%), hypertension (46.
    7%), and elevated AST (40.
    0%).
    46.
    7% of patients observed AEs above grade 3, and the most common was hypertension (20.
    0 %); Level 4 and 5 TRAE are not observed

    Gerolizumab is an IgG4K monoclonal antibody expressed in CHO cells, with a completely new amino acid sequence and molecular structure that is different from the anti-PD-1 monoclonal antibody already on the market.

    The new drug marketing application of gerolizumab was officially accepted by the National Medical Products Administration (NMPA) on July 20, 2020, and was included in priority review for the treatment of relapsed and refractory peripheral T-cell lymphoma (PTCL).
    ), the first anti-PD-1 monoclonal antibody to apply for PTCL indication in the world.

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.